The Latest Cardiac and Vascular News
NEW YORK, July 31, 2024 /PRNewswire/ — An artificial intelligence program created explanations of heart test results that were in most cases accurate, relevant, and easy to understand by patients, a new study finds. The study addressed the echocardiogram (echo), which uses sound waves to…
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company’s AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death […]
HOPEWELL, N.J. , July 29, 2024 /PRNewswire/ — The aorta is the largest blood vessel in the body, and diseases or injury to the aorta can be life threatening. Offering the latest advance in minimally invasive surgery to restore function to damaged aortas, vascular surgeons at Capital…
Thought leaders, trailblazers, and advocates gather to explore the forefront of discoveries and advance partnerships between medicine and technology. ATLANTA, July 29, 2024 /PRNewswire/ — The Heart Rhythm Society (HRS) is preparing for its third annual HRX event, bringing cardiovascular…
Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease
July 25, 2024 06:00 AM Eastern Daylight Time HOUSTON–(BUSINESS WIRE)–The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR’s TAH […]
In a study conducted by Brigham & Women’s Hospital, Nanox.AI-Based Analysis helps Reveal Coronary Artery Calcium in over 50% of IMID Patients; Lead author Brittany Weber, MD, PhD, declared as ‘Young Investigator Awards’ Winner
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the confirmatory Phase 3 trial of its autologous CardiAMP cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction (HFrEF) has commenced enrollment in the United States.
July 24, 2024 04:15 PM Eastern Daylight Time IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement to acquire JenaValve Technology, […]
July 24, 2024 09:07 AM Eastern Daylight Time KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc., a leader in AI-powered blood tests for cardiovascular diagnostics, announces that the United States Patent and Trademark Office has issued a patent for its highly accurate blood test, HART CADhs, which assesses a patient’s risk of obstructive coronary artery […]
